platforms

Normunity was founded to be an integrated engine for novel immuno-oncology drug discovery, seamlessly connecting groundbreaking research into the clinic. Together with the lab of Dr. Lieping Chen, a luminary in the field of immuno-oncology, our drug discovery enterprise is designed to discover new therapies to reach more cancer patients by identifying and targeting novel mechanisms that block normal cancer-fighting immunity.

AN INTEGRATED ENGINE FOR NOVEL I-O DRUG DISCOVERY

Chen Lab DISCOVERY PLATFORM

Identify and validate novel targets

Deep target understanding

Generate hypothesis

Engineering platforms

Proposed biomarkers

Testing in animal models

Continuous enriching target understanding

Normunity Drug DEVELOPMENT

Develop novel medicines

Fully human monoclonal antibodies

Further animal testing

Chemistry, manufacturing and controls

Regulatory requirements

Clinical planning including Biomarker selection

Market strategy

Normunity Drug DEVELOPMENT

Our unique collaborative and iterative workflow is purpose-built to exchange scientific ideas, share key reagents and tools, and nurture basic science into clinical application. The Chen lab initiates hypothesis generation and building the essential assays to identify and validate novel targets. While the lab continues to interrogate the fundamental biology of targets, Normunity translates the target findings into drug candidates utilizing our deep experience in monoclonal antibody design and engineering and drug development.

UNCOVERING NOVEL I-O MECHANISMS REQUIRES NEW PLATFORM CAPABILITIES

Because normal cancer-fighting immunity is disrupted by the cancer itself and involves multiple mechanisms, it difficult to study by conventional target-based methodologies. Our ability to target novel mechanisms is based on proprietary capabilities developed by the Chen lab using high throughput, physiologically relevant, phenotypic screening platforms to systematically interrogate the interactions between cancer and the immune system.

Key attributes of proprietary platforms enable us to reveal intersection points between cancer and the immune system

High
throughput

Simultaneous testing thousands of potential mechanisms

 
Unbiased

Interrogation of mechanisms without pre-supposed solution

Physiologically
Relevant

Utilize human cells and tissues

Rapid target
Deconvolution

Identify target that underlies observed phenotypic response

These proprietary platforms are building a comprehensive view of how the immune response malfunctions in cancer, revealing specific functional receptors and ligands that block the normal work of immune cells, including cytotoxic T-cells.

Back to Top